Brief: Aclaris Therapeutics Q2 Net Income USD -15.429 Million Vs. IBES Estimate USD -16.4 Million

Aclaris Therapeutics

07/08/2025 12:00

Overview

Aclaris Q2 revenue beats analyst expectations despite yr/yr decline, per LSEG data

Net income for Q2 beats analyst estimates despite reporting a net loss, per LSEG data

Co expects cash runway to fund operations into the second half of 2028

Outlook

Company expects cash runway to fund operations into H2 2028

Aclaris exploring non-dilutive opportunities to extend cash runway

Company anticipates Phase 2 bosakitug results in H2 2026

Aclaris expects Phase 1a ATI-052 results by early 2026

Result Drivers

PHASE 2A TRIAL - Positive results from ATI-2138 trial confirm tolerability and show strong efficacy signal, validating ITK as therapeutic target

REPORTED LOSS - Net loss was $15.4 million for the second quarter of 2025 compared to $11.0 million for the second quarter of 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$1.78 mln
$1.37 mln (7 Analysts)
Q2 Net Income
Beat
-$15.43 mln
-$16.40 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Aclaris Therapeutics Inc is $7.00, about 77.9% above its August 6 closing price of $1.55

Press Release: ID:nGNX9H6Xjk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)